Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$5.00??? Wow, really??
I see a PPS of $5.00 by year end,jmho
Yawn...the time to get excited or optimistic is when the pps sustains any upward mobility. Getting back to its all-time PPS of $7.70USD, would be a great start, or a buy-out, which I believe is the likely scenario.
Thanks John:)
Agreed. Futures action is not impressive at this time.
At first glance, the numbers look great. Now, let's see what the market says today.
Organigram beats on revenue
Jan. 11, 2022 6:04 AM ETOrganiGram Holdings Inc. (OGI)By: Meghavi Singh, SA News Editor
Organigram (NASDAQ:OGI): FQ1 Net loss of $1.31M vs. net loss of $34.34M a year ago quarter.
Revenue of $30.38M (+57.2% Y/Y) beats by $7.1M.
Press Release
Q1 Fiscal 2022 adjusted gross margin was $5.5 million, or 18% of net revenue, compared to $1.9 million, or 10%, in Q1 Fiscal 2021.
Q1 Fiscal 2022 negative adjusted EBITDA improved to $1.9 million compared to $5.7 million in Q1 Fiscal 2021.
“Our positive outlook for 2022 is further bolstered by the addition of Laurentian’s premium products to our portfolio, with an increased presence in Quebec and the resumption of international sales, which will continue through the year. We are also pleased with our continued progress at improving economies of scale in our operations, thus reducing operating costs and driving significant improvements in adjusted gross margin and adjusted EBITDA. While we previously projected to achieve positive adjusted EBITDA in Q4, with the purchase of Laurentian that will be accelerated to Q3 Fiscal 2022," said Beena Goldenberg.
https://seekingalpha.com/news/3786958-organigram-beats-on-revenue?messageid=2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+News+Smart
OGI NEWS December 22nd, 2021...
Organigram Makes Additional $2.5 Million Investment in Hyasynth Biologicals, a Leading Cannabinoid Biosynthesis Company
With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans
MONCTON, New Brunswick--(BUSINESS WIRE)--As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI), (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, and Hyasynth Biologicals Inc. (“Hyasynth”) a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis are pleased to announce that Organigram has acquired an additional $2.5 million of secured convertible debentures in Hyasynth (the “Debentures”). Additionally, the parties have amended certain of the Debentures’ terms purchased by Organigram from Hyasynth in previous tranches. Proceeds of the investment are designated to advance Hyasynth’s production scalability as well as investment into new cannabinoid technologies (including rare cannabinoids), business development efforts and company growth.
“Hyasynth’s advantage lies with its unique products derived from natural sugars and proprietary enzyme engineering.”
In September 2018, Organigram acquired $5.0 million of Hyasynth Debentures followed by an additional $2.5 million in October 2020. Today’s transaction brings Organigram’s total investment in Hyasynth to $10.0 million building upon previously completed milestones and recent successes of the company in advancing technology and business development. Organigram retains its two nominees to Hyasynth’s Board of Directors comprised of seven members.
In addition, Organigram continues to be a preferred partner for Hyasynth and has the option to purchase Hyasynth’s cannabinoids, subject to the terms of its agreement with Hyasynth, at a discount to the wholesale market price for a period of ten years from the date of Hyasynth’s commencement of commercial production.
“Organigram continues to be extremely focused on delivering meaningful innovation to cannabis consumers, which is why we are so excited about deepening our relationship with Hyasynth. They have achieved tremendous scientific advancement in the cannabinoid biosynthesis space with technology expected to be protected by intellectual property,” said Beena Goldenberg, Chief Executive Officer of Organigram. “Our review noted that its pathway provides greater catalytic efficiency and streamlines strain optimization which should make it more scalable than some of its competitors’ pathways. We remain committed to our investment in this strategic partner and look forward to helping Hyasynth advance its commercialization efforts.”
“Hyasynth is now at a key inflection point in bringing our products to market. Organigram has been an exceptional partner and this follow-on investment will enable us to bridge into an exciting 2022 where we intend to launch large scale production with commercial partners,” said Kevin Chen, Chief Executive Officer and Co-founder of Hyasynth. “We’ve demonstrated our ability not only to achieve scalable production of CBD/CBDA but also improve the cost of production exponentially. We are in the process of developing a series of rare cannabinoids to ultimately become the supplier of choice for sustainable and high-quality ingredients.”
Strategic Rationale
“When considering the enormous opportunity that lies ahead for cannabinoids in the medical, wellness and recreational spaces, and how they intersect with evolving research and regulatory frameworks being considered globally, we see biosynthesis as a crucial path in developing key active ingredients for cannabis-based products,” said Paolo De Luca, Chief Strategy Officer of Organigram. “Hyasynth’s advantage lies with its unique products derived from natural sugars and proprietary enzyme engineering.”
Biosynthesis is most commonly known as the primary production methodology for insulin used in the treatment of diabetes. Unlike chemical synthesis, or agricultural methods, biosynthesis results in products and final ingredients that are pesticide-free and are based on natural ingredients. Hyasynth’s biosynthesis process uses patent-pending yeast strains and enzymes to produce pure cannabinoids (not synthetic) without relying on cannabis plants. In addition to the major cannabinoids such as CBD and THC, Hyasynth has also demonstrated and submitted patent applications on the production of rare cannabinoids for which traditional cultivation is cost prohibitive since these cannabinoids are found in only very low levels in cannabis plants. Rare cannabinoids are believed to be the next frontier of cannabis research and novel cannabis product development.
The advantages of biosynthesis compared to traditional plant cultivation are expected to be as follows:
feasible production of rare cannabinoids;
reduced operating and capital costs;
consistency and purity of products (e.g. CBD without THC);
smaller environmental footprint; and
leverages existing infrastructure and techniques already popular for food and pharmaceutical ingredient production.
About Hyasynth Biologicals Inc.
Hyasynth Biologicals Inc. is a Montreal, Canada based technology company that produces pure and sustainable products through fermentation. It was founded in 2014 to satisfy a growing demand for cannabinoids by the pharmaceutical and consumer markets. Hyasynth’s proprietary fermentation technology enables scalable, low-cost production of THC, CBD, CBG, and rare cannabinoids not typically accessible by plant cultivation. Investors in Hyasynth include the venture capital firm SOSV and IndieBio, AngesQuebec, and the strategic investor, Organigram Holdings inc. For more information see www.hyasynthbio.com
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include: Organigram Inc., a licensed producer of cannabis and cannabis-derived products in Canada, The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews in Canada and Laurentian Organic Inc., a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Monjour, Big Bag o’ Buds, SHRED, Trailblazer, Tremblant and Laurentian. Organigram's facility is located in Moncton, New Brunswick with other manufacturing facilities in Winnipeg, Manitoba and Lac-Supérieur (near Mt. Tremblant), Quebec . The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information including achievement of milestones, prospects for biosynthesis and factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
https://investors.organigram.ca/press-releases/organigram-makes-additional-25-million-investment-in-hyasynth-biologicals-a-leading
Contacts
For Organigram Investor Relations enquiries:
investors@organigram.ca
For Organigram Media enquiries:
Megan McCrae, Senior Vice President, Marketing and Communications
megan.mccrae@organigram.ca
For Hyasynth enquiries:
Kevin Chen, Chief Executive Officer and Co-founder
kevin.chen@hyasynthbio.com
Sign up to get full access to all our latest press releases.
Moncton
35 English Drive
Moncton, NB, E1E 3X3
Toronto
Bay Adelaide Centre
1250-333 Bay Street
Toronto, ON, M5H 2R2
.
Anything new?
OGI Yes, all good fun here!
Thank you john1311 !
OrganiGram Holdings Inc. 2021 Q4 - Results - Earnings Call Presentation
Nov. 23, 2021 9:02 AM ETOrganiGram Holdings Inc. (OGI)
https://seekingalpha.com/article/4471428-organigram-holdings-inc-2021-q4-results-earnings-call-presentation?utm_campaign=RTA+Articles&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+Article+Smart
Organigram Reports Fourth Quarter Fiscal 2021 Results
Nov. 23, 2021 6:00 AM ETOrganiGram Holdings Inc. (OGI)
Continued growth in net revenue and increased market share
Achieved a 7% share of market in the recreational cannabis market in Q4, up from 5.4% in Q3 2021, positioning Organigram (OGI) as the #4 licensed producer and the momentum continues with a 7.9% share of market as of October.1
24% growth in gross revenue to $36.2 million in Q4 2021 from Q3 2021 and 43% from the same prior-year period
22% growth in net revenue to $24.9 million in Q4 2021 from Q3 2021 and 22% from the same prior-year period
36% growth in recreational net revenue to $22.9 million in Q4 2021 from Q3 2021 and 52% from the same prior-year period
https://seekingalpha.com/pr/18573712-organigram-reports-fourth-quarter-fiscal-2021-results
Organigram beats on revenue
Nov. 23, 2021 6:02 AM
Revenue of $24.87M (+21.9% Y/Y) beats by $6.19M.
https://seekingalpha.com/news/3773641-organigram-beats-on-revenue?utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+News+Smart
That's what stocks do, they move-up and down. OGI
What is wrong with this company!? One day it has great press and does well, then the bottom drops out. Very frustrating.
KK thanks for the heads up
OGI has been pretty active lately:)
With Beena G. now as CEO this stock is headed in only one direction. Just look at what she did at Supreme to see which way that is.
Cool Beans Thanks Bud
OGI "According to MarketBeat, OrganiGram has a consensus rating of “Hold” and a consensus target price of $4.21." https://finance.yahoo.com/m/ebbf8b2c-30fa-32b6-be1e-c0eed6072138/why-green-thumb-industries-.html
Anything new happening?
"Organigram Holdings Inc. Files Final Base Shelf Prospectus"...
"The Base Shelf Prospectus enables Organigram to qualify the distribution of up to C$500,000,000 of common shares, preferred shares, debt securities, subscription receipts, warrants, and units during the 25-month period that the Base Shelf Prospectus remains effective. The specific terms of any future offering of securities will ?be established in a prospectus supplement filed with the applicable Canadian and US regulatory authorities. The Base Shelf Prospectus will provide flexibility for financing options to pursue the Corporation’s objectives." https://investors.organigram.ca/press-releases/organigram-holdings-inc-files-final-base-shelf-prospectus
OGI
.
Edibles is getting to be a more popular delivery process as time progresses
~NEWS~ High-quality, Value-priced SHRED’ems Gummies.....
"Organigram Extends Popular SHRED Product Portfolio with High-quality, Value-priced SHRED’ems Gummies"
Captures #1 share of edibles position in inaugural launch province of PEI within two weeks of launch August 25th, 2021
MONCTON, New Brunswick--(BUSINESS WIRE)-- Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce the launch of SHRED’ems, a high-quality and bold flavoured lineup of cannabis-infused gummies. SHRED’ems is an extension of the Company’s highly popular, value-priced SHRED product portfolio which includes SHRED milled flower and SHRED Jar of Joints. Since launch in early August, SHRED’ems has already demonstrated great momentum, capturing the leading market share position of the edibles category in Prince Edward Island (PEI) within 2 weeks of launch and the fourth position in New Brunswick.
Reflecting the SHRED portfolio’s commitment to value, convenience, and bold flavour, SHRED’ems is expected to be the one of the most competitively priced gummies on the market, and is available in three bold, all-natural flavours. SHRED’ems gummies are also vegan friendly. Flavours include:
Wild Berry Blaze (Hybrid): A juicy blend of sweet blueberry and raspberry, Wild Berry Blaze is available in a package of 4 gummies containing 2.5 mg THC and 10mg CBD per gummy
Sour Cherry Punch (Indica): Sweet, tart and tangy, Sour Cherry Punch is available in a package of 2 gummies containing 5 mg THC per gummy
Sour Megamelon (Sativa): A bold watermelon flavour with a sour tang, Sour Megamelon is also available in a package of 2 gummies containing 5 mg THC per gummy
These gummies are the first Organigram products to be crafted by The Edibles & Infusions Corporation (“EIC”), the high-capacity gummy manufacturer Organigram acquired in April 2021.
“The launch of SHRED’ems is a significant milestone for Organigram,” says Tim Emberg, Chief Revenue Officer, Organigram. “As a company, we remain dedicated to developing industry-leading products that meet consumer needs, and the launch of SHRED’ems is the first of many new innovations we anticipate coming from our strategic acquisition of EIC.”
Gummies currently represent 74% of the edibles category, which continues to be a rapidly growing and increasingly important segment of the Canadian market.
“Entering this profitable and important category represents a tremendous opportunity for Organigram,” adds Emberg. “EIC’s outstanding confectionary experience and operational expertise means we are able to deliver a significant volume of product while minimizing costs – savings that ultimately get passed along to the SHRED’ems consumer– and a strategy that is designed to help build Organigram’s leadership in this space.”
“We’re excited to be part of this product and business evolution,” James Fletcher, President, EIC. “We are proud of the positive impact our streamlined processes can have on both efficiency and cost. We look forward to collaborating on a long line of product innovations.”SHRED’ems is currently available at retailers in British Columbia, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland, and Prince Edward Island and is expected to be available in Ontario and Nova Scotia by mid-September.
The launch of SHRED’ems and the first listing in certain provinces marks the achievement of the first earnout milestone resulting in an additional $3.5 million in common shares being payable to the EIC vendors under the previously disclosed terms of the share purchase agreement for EIC and subject to the terms and conditions thereof. Milestone payments paid in common shares shall be priced based on the volume weighted average trading price for the five days preceding the date of issuance. For more information about SHRED’ems, visit https://www.shredcann.com/
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include: Organigram Inc., a licensed producer of cannabis and cannabis-derived products in Canada and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews and candy in Canada.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Indi, Bag o’ Buds, SHRED and Trailblazer. Organigram’s facility is located in Moncton, New Brunswick with another manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans,” “expects,” “estimates,” “intends,” “anticipates,” “believes” or variations of such words and phrases or state that certain actions, events, or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include the market position of SHRED’ems and other products from time to time, the relative performance of products in different provincial jurisdictions and factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Performance in certain provinces may not be indicative of performance in other provinces. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
For Investor Relations enquiries:
Amy Schwalm
Vice President, Investor Relations
Amy.Schwalm@organigram.ca
(416) 704-9057
For Media enquiries:
Marlo Taylor
mtaylor@gagecommunications.ca
https://investors.organigram.ca/organigram-extends-popular-shred-product-portfolio-with-high-quality-value-priced-shredems-gummies
Anything new that I might have missed?
An interesting article...hope it comes to fruition...
https://cannabisinvestingnewsletter.com/2021/08/20/organigram-ogi-stock-will-see-its-day-and-move-up/
Same here
riding house money in some canadian producers
and moved to some US MSO's too
nice move by OGI today.
Thanks for the OrganiGram (OGI) UPDATE, BubbaInSC......
"OrganiGram too disclosed its fiscal third quarter of 2021 results recently and reported net revenue of $20.3 million for the period ended in May. This indicated a sequential increase of 39% year over year compared to sales of $14.6 million in fiscal Q2.
While OGI stock spiked soon after its quarterly results, it has since lost over 12% in market value in the last three weeks. Despite the pullback, OGI has returned 87% to investors year to date.
But investors should note that OrganiGram’s profit margins do not inspire confidence. In Q2, the company reported a gross loss of $17.2 million. While its gross profit improved to $2.1 million in the May quarter it was on the back of fair value adjustments. OGI confirmed it does not expect gross margins to improve in Q4 but claimed the management team has identified multiple cost efficiency opportunities that will be implemented going forward.
In fiscal Q3, OGI’s operating expenses totaled $13.6 million accounting for 65% of net sales. The company ended the quarter with less than $200 million in the bank which suggests it will need to raise additional capital in the upcoming months which will dilute shareholder wealth."
.
Thanks Hunch, I sold all of my Canadian shares a few years ago and moved my funds into the US MSO's. Been really happy with that move.
Was good for me! Different timing maybe Always good to see you Etailer.
When I don't like a stock I sell and move on, I've made money here many times
Same old same old. It's been a crappy long term investment at best. Glad I got out of this one a few years ago along with Aurora and Canopy.
"Organigram Launches Cannabis Innovators Panel" https://investors.organigram.ca/organigram-launches-cannabis-innovators-panel
OGI
"Organigram Reports Third Quarter Fiscal 2021 Results" https://investors.organigram.ca/organigram-reports-third-quarter-fiscal-2021-results
OGI
Whats happening with OGI these days?
Yes that is the ticker for this group, OGI. My post mentioned Tilray because it drives the market as do others. Hopefully it comes back soon. GLTA
OGI 'OrganiGram Holdings Inc. (TSX:OGI)'
Looks like Tilray just found their new low at 13.90. My guess is day traders will rebound the market to make their income.
Followers
|
181
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11332
|
Created
|
08/27/14
|
Type
|
Free
|
Moderators WALL STREET KID Hunchbackgeek |
Efficient Vertical Growth Infrastructure! | 137 000 sq ft. Expansion Under Construction! | Recreational Edibles Coming! |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |